Topical corticosteroids in the era of new topical therapies: Balancing efficacy and safety for long-term use

Alexander Egeberg^{1

2}, Jacob P Thyssen^{1

2}

Affiliations

¹ Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
² Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Editorial

Alexander Egeberg et al. J Eur Acad Dermatol Venereol. 2024 Jul.

. 2024 Jul;38(7):1236-1237.

doi: 10.1111/jdv.20041.

Alexander Egeberg^{1

2}, Jacob P Thyssen^{1

2}

¹ Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
² Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

No abstract available

References

1. Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol. 1996;13(3):239–245.
1. Ohman EM, Rogers S, Meenan FO, McKenna TJ. Adrenal suppression following low‐dose topical clobetasol propionate. J R Soc Med. 1987;80(7):422–424.
1. Hsieh B‐J, Shen D, Chan TC, Cho YT, Tang CH, Chu CY. Higher cumulative dose of topical corticosteroids is associated with osteoporosis and major osteoporotic fracture: a nationwide case–control study. J Eur Acad Dermatol Venereol. 2024;38:1347–1356.
1. Egeberg A, Schwarz P, Harsløf T, Andersen YMF, Pottegård A, Hallas J, et al. Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures. JAMA Dermatol. 2021;157(3):275–282.
1. Gether L, Storgaard H, Kezic S, Jakasa I, Hartmann B, Skov‐Jeppesen K, et al. Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis ‐ a randomized controlled study. Allergy. 2023;78(7):1964–1979.